Re: "Naratriptan in the prophylaxis of transformed migraine" (Sheftell FD Rapoport AM, Coddon DR. Headache.1999,39:506-510).
Warner
J S
JS
D006801:Humans; D007211:Indoles / Q000009:adverse effects / Q000627:therapeutic use*; D008881:Migraine Disorders / Q000503:physiopathology* / Q000517:prevention & control*; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use*; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use*; D014363:Tryptamines; D014662:Vasoconstrictor Agents / Q000009:adverse effects / Q000627:therapeutic use*
D007211:Indoles; D010880:Piperidines; D017366:Serotonin Receptor Agonists; D014363:Tryptamines; D014662:Vasoconstrictor Agents; C106783:naratriptan